The European Medicines Agency is insisting that the benefits of AstraZeneca's covid-19 vaccine outweigh the risk of side effects.
The Agency held a meeting today after a number of EU countries, including Ireland, suspended the use of the AstraZeneca jab.
The decision was made after a small number of patients who received the jab developed blood clots.
30,000 people here will not receive the vaccine as expected this week as a result of the suspension.
The EMA is continuing to review the situation with an update due on Thursday.
However, for now, it says there is no indication that the vaccination has caused the blood clot issues that have led to a number of countries suspending its use.
